Federal Register / Vol. 62, No. 5 / Wednesday, January 8, 1997 / Notices 1121

Health Resources and Services

Administration (HRSA) will publish

periodic summaries of proposed

projects being developed for submission

to OMB under the Paperwork Reduction

Act of 1995. To request more

information on the proposed project or

to obtain a copy of the data collection

plans and draft instruments, call the

HRSA Reports Clearance Officer on

(301) 443–1129.

Comments are invited on: (a) Whether

the proposed collection of information

is necessary for the proper performance

of the functions of the agency, including

whether the information shall have

practical utility; (b) the accuracy of the

agency’s estimate of the burden of the

proposed collection of information; (c)

ways to enhance the quality, utility, and

clarity of the information to be

collected; and (d) ways to minimize the

burden of the collection of information

on respondents, including through the

use of automated collection techniques

or other forms of information

technology.

Proposed Projects

1. Loan Information System Records

for the DHHS and DHUD Hospital

Mortgage Insurance, Guarantee, and

Direct Loan Programs (OMB No. 0915–

0174)—Extension, no change—The

Division of Facilities Loans within the

Health Resources and Services

Administration monitors outstanding

direct and guaranteed loans made under

Section 621 of Title VI and Section 1601

of Title XVI of the Public Health Service

Act, as well as loans insured under the

Section 242 Hospital Mortgage

Insurance Program of the Fair Housing

Act. These programs were designed to

aid construction and modernization of

health care facilities by increasing the

access of facilities to capital through the

assumption of the mortgage credit risk

by the Federal Government.

Operating statistics and financial

information are collected annually from

hospitals with mortgages that are

insured under these programs. The

information is used to monitor the

financial stability of the hospitals to

protect the Federal investment in these

facilities. The form used for the data

collection is the Hospital Facility Data

Abstract. No changes in the form are

proposed. Because of the relatively

small level of effort associated with

submitting this report, there are no

plans to develop a system for electronic

transmission of the data. The estimate of

annual burden hours is as follows:

Form No. of respondents

Responses

per respondent

Hours per

response

Total hour

burden

Hospital Facility Data Abstract ................................ 250 hospitals .......................................................... 1 1 hour ...... 250 hours.

Send comments to Patricia Royston,

HRSA Reports Clearance Officer, Room

14–36, Parklawn Building, 5600 Fishers

Lane, Rockville, MD 20857. Written

comments should be received within 60

days of this notice.

Dated: January 2, 1997.

J. Henry Montes,

Director, Office of Policy and Information

Coordination.

[FR Doc. 97–424 Filed 1–7–97; 8:45 am]

BILLING CODE 4160–15–P

National Institutes of Health

Submission for OMB Review;

Comment Request; Pilot Research for

Epidemiologic Studies of Migrant and

Seasonal Farmworkers

SUMMARY: Under the provisions of

Section 3506(c)(2)(A) of the Paperwork

Reduction Act of 1995, the National

Cancer Institute (NCI), the National

Institutes of Health (NIH) has submitted

to the Office of Management and Budget

(OMB) a request to review and approve

the information collection listed below.

This proposed information collection

was previously published in the Federal

Register on October 24, 1996, page

55159, and allowed 60 days for public

comment. No public comments were

received. The purpose of this notice is

to allow an additional 30 days for public

comment. The National Institutes of

Health may not conduct or sponsor, and

the respondent is not required to

respond to, any information collection

that has been extended, revised, or

implemented after October 1, 1995,

unless it displays a currently valid OMB

control number.

Proposed Collection

Title: Pilot Research for

Epidemiologic Studies of Migrant and

Seasonal Farmworkers. Type of

Information Collection Request: New.

Need and Use of Information Collection:

A pilot study will be conducted to

evaluate the ability to trace farmworkers

over extended periods of time, to

determine cancer diagnosis and

treatment patterns among migrant and

seasonal farmworkers, and to assess the

reliability of farm work histories from

farmworkers and from their spouses.

The information will be used by the NCI

to identify the most appropriate study

design, case ascertainment procedures,

and exposure assessment methods for a

full-scale epidemiologic study of cancer

among migrant and seasonal

farmworkers. Determining the feasibility

of using automated data collection

techniques to obtain occupational

histories from farmworkers will be part

of this project. Frequency of Response:

One-time study. Affected public:

Individuals or households. Type of

Respondents: Farmworkers and

relatives. The annual reporting burden

is as follows:

Type of respondents Estimated No.

of respondents

Estimated No.

of responses

per respondent

Average burden hours per

response

Estimated total

annual burden

hours requested

Farmworkers ..................................................................................................... 78 1.0 .333 26

Farmworkers with family history of cancer ....................................................... 67 1.0 .167 11

Farmworkers’ relatives with cancer .................................................................. 33 1.0 .333 11

Farmworkers and spouses ............................................................................... 53 1.2 1.000 64

Farmworker Opportunity Program Clients ........................................................ 13,333 1.0 .167 2,222

Total ....................................................................................................... 2,334
1122 Federal Register / Vol. 62, No. 5 / Wednesday, January 8, 1997 / Notices

There are no Capital Costs, Operating

Costs, and/or Maintenance Costs to

report.

REQUEST FOR COMMENTS: Written

comments and/or suggestions from the

public and affected agencies are invited

on one or more of the following points:

(1) Whether the proposed collection or

information is necessary for the proper

performance of the function of the

agency, including whether the

information will have practical utility;

(2) The accuracy of the agency’s

estimate of the burden of the proposed

collection of information, including the

validity of the methodology and

assumptions used; (3) Ways to enhance

the quality, utility, and clarity of the

information to be collected; and (4)

Ways to minimize the burden of the

collection of information on those who

are to respond, including the use of

appropriate automated, electronic,

mechanical, or other technological

collection techniques or other forms of

information technology.

FOR FURTHER INFORMATION CONTACT:

To request more information on the

proposed project or to obtain a copy of

the data collection plans and

instruments, contact Dr. Shelia Hoar

Zahm, Project Officer, National Cancer

Institute, Executive Plaza North, Room

418, Rockville, MD 20892–7364, or call

non-toll-free number (301) 496–9093, or

FAX your request to (301) 402–1819, or

E-mail your request, including your

address, to ZahmS@epndce.nci.nih.gov.

COMMENTS DUE DATE: Comments

regarding this information collection are

best assured of having their full effect if

received on or before February 7, 1997.

Dated: December 6, 1996.

Nancy L. Bliss,

OMB Project Clearance Liaison.

[FR Doc. 97–334 Filed 1–7–97; 8:45 am]

BILLING CODE 4140–01–M

National Institutes Of Health

National Eye Institute; National

Institute of Arthritis and

Musculoskeletal and Skin Diseases:

Licensing Opportunity and/or

Opportunity for a Cooperative

Research and Development Agreement

(CRADA) for the Use of Antiflammins

AGENCY: National Institutes of Health,

Public Health Service, HHS.

ACTION: Notice.

SUMMARY: The National Institutes of

Health is seeking licensees and/or

CRADA partners for the further

development and commercialization of

its patent portfolio for antiflammins.

The inventions claimed in U.S. Patent

No. 5,266,562 issued 30 Nov 1993,

‘‘Anti-Inflammatory Agents,’’ are

available for either exclusive or nonexclusive licensing (in accordance with

35 U.S.C. 207 and 37 CFR Part 404) and/

or further development under one or

more CRADAs in several clinically

important applications as described

below in the Supplementary

Information.

To speed the research, development

and commercialization of this new class

of drugs, the National Institutes of

Health is seeking one or more license

agreements and/or CRADAs with

pharmaceutical or biotechnology

companies in accordance with the

regulations governing the transfer of

Government-developed agents. Any

proposal to use antiflammins in the

treatment of inflammatory disease

processes will be considered.

ADDRESSES: CRADA proposals and

questions about this opportunity should

be addressed to: Ms. Sue Patow, Office

of Technology Transfer, National Heart,

Lung, and Blood Institute, Building 31,

Room 1B30, Bethesda, MD 20892 (301/

402–5579). CRADA proposals must be

received by the date specified below.

Licensing proposals and questions

about this opportunity should be

addressed to: Ms. Carol Lavrich, Office

of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Rockville, MD 20852 (301/

496–7735 ext. 287). Respondees

interested in licensing the invention

will be required to submit an

Application for License to Public Health

Service Inventions. Respondees

interested in submitting a CRADA

proposal should be aware that it may be

necessary to secure a license to the

above patent rights in order to

commercialize products arising from a

CRADA agreement.

DATES: There is no deadline by which

license applications must be received.

CRADA proposals must be received on

or before April 8, 1997.

SUPPLEMENTARY INFORMATION:

Antiflammins are biologically active

synthetic oligopeptides, derived from

the sequence similarity between lipocortin-1 and uteroglobin, an antiflammatory protein. These peptides

have antiphospholipase A2 and

immunomodulatory properties. Because

of the great therapeutic potential of

specific and potent antiflammin drugs

that may be developed, scientists in

several Institutes at the National

Institutes of Health are examining the

use of antiflammins in the treatment of

Health are examining the use of

antiflammins in the treatment of a

variety of inflammatory processes,

including acute anterior ocular

inflammation (uveitis) and psoriasis.

Dr. Chi-Cho Chan, a clinical

investigator at the National Eye Institute

(NEI), has an IND for the use of

antiflammin 2 in acute anterior uveitis,

and seven patients have previously been

enrolled in a clinical trial. To date, no

toxicity has been observed in patients

treated with this drug. Dr. Chan and Dr.

Whitcup at the NEI are interested in

developing new topical formulations of

antiflammins and the initiation of multicenter randomized clinical trials of

antiflammins for the treatment of

anterior uveitis, post-operative ocular

inflammation, and allergic

conjunctivitis.

Dr. John DiGiovanna, an investigator

in the National Institute of Arthritis and

Musculoskeletal and Skin Diseases

(NIAMS), is studying the use of

antiflammins to treat psoriasis, a

hyperproliferative inflammatory skin

disease. Dr. DiGiovanna would like to

continue these studies with a

collaborator capable of expanding these

studies to include other inflammatory

skin diseases such as atopic and contact

dermatitis, as well as develop animal

and in vitro models to study the effects

of antiflammins on skin.

In addition, Dr. Dimitrios T.

Boumpas, also of NIAMS, is studying

the use of anti-inflammatory/

immunosuppressive compounds to treat

psoriatic arthritis, rheumatoid arthritis,

and systemic lupus erythematosus. Dr.

Boumpas would like to initiate studies

with a collaborator to investigate the

effects of antiflammins in animal

models of these diseases including

toxicity studies and its use and toxicity

in patients with autoimmune rheumatic

diseases.

CRADA aims include the rapid

publication of research results and the

timely exploitation of commercial

opportunities. The CRADA partner(s)

will enjoy rights of first negotiation for

licensing Government rights to any

inventions arising under the agreement

and will be expected to advance funds

payable upon signing the CRADA to

help defray Government expenses for

patenting such inventions and other

CRADA-related costs.

The role of the NEI and NIAMS in

these CRADAs will be as follows:

1. Provide the Collaborator(s) with

samples of the subject compounds for

pharmaceutical evaluation.

2. Continue the detailed

physicochemical characterization of the

test compounds as well as research on

their mechanism of biological action,

and publish these results and provide